Skip to Content
Merck
  • Single-Cell RNA-Seq Reveals Dynamic Early Embryonic-like Programs during Chemical Reprogramming.

Single-Cell RNA-Seq Reveals Dynamic Early Embryonic-like Programs during Chemical Reprogramming.

Cell stem cell (2018-06-26)
Ting Zhao, Yao Fu, Jialiang Zhu, Yifang Liu, Qian Zhang, Zexuan Yi, Shi Chen, Zhonggang Jiao, Xiaochan Xu, Junquan Xu, Shuguang Duo, Yun Bai, Chao Tang, Cheng Li, Hongkui Deng
ABSTRACT

Chemical reprogramming provides a powerful platform for exploring the molecular dynamics that lead to pluripotency. Although previous studies have uncovered an intermediate extraembryonic endoderm (XEN)-like state during this process, the molecular underpinnings of pluripotency acquisition remain largely undefined. Here, we profile 36,199 single-cell transcriptomes at multiple time points throughout a highly efficient chemical reprogramming system using RNA-sequencing and reconstruct their progression trajectories. Through identifying sequential molecular events, we reveal that the dynamic early embryonic-like programs are key aspects of successful reprogramming from XEN-like state to pluripotency, including the concomitant transcriptomic signatures of two-cell (2C) embryonic-like and early pluripotency programs and the epigenetic signature of notable genome-wide DNA demethylation. Moreover, via enhancing the 2C-like program by fine-tuning chemical treatment, the reprogramming process is remarkably accelerated. Collectively, our findings offer a high-resolution dissection of cell fate dynamics during chemical reprogramming and shed light on mechanistic insights into the nature of induced pluripotency.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human SOX17
Sigma-Aldrich
MISSION® esiRNA, targeting human POU5F1 (2)
Sigma-Aldrich
MISSION® LentiPlex® Mouse Pooled shRNA Library, For Rapid, Convenient Genome-wide shRNA Screens
Sigma-Aldrich
Triton X-100, for molecular biology
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
MISSION® esiRNA, targeting human DPPA2